吉非替尼联合全脑放疗在表皮生长因子受体突变型非小细胞肺癌脑转移患者中的疗效与安全性OA

Objective:To evaluate the efficacy and safety of gefitinib combined with whole-brain radiotherapy(WBRT)in patients with epidermal growth factor receptor(EGFR)-mutant non-small cell lung cancer(NSCLC)with brain metastases.Method:Clinical data of 84 patients with EGFR-mutant NSCLC and brain metastases diagnosed at Shuyang Hospital of Traditional Chinese Medicine between January 2021 and December 2023 were retrospectively analyzed.According to treatment modality,patients were divided into a control group(gefitinib monotherapy)and a combination group(gefitinib plus WBRT),with 42 patients in each group.Intracranial objective response rate(iORR),intracranial disease control rate(iDCR),progression-free survival(PFS),overall survival(OS),and adverse events were compared between the two groups.Result:The iORR in the combination group was 71.4％,significantly higher than that in the control group(47.6％),and the iDCR was also higher in the combination group(P＜0.05).The median PFS was significantly longer in the combination group than in the control group(P＞0.05).The median OS was 20.2 months in the combination group and 16.4 months in the control group,with a statistically significant difference(P＜0.05).There was no significant difference in the incidence of grade ≥ 3 adverse events between the two groups.Conclusion:Gefitinib combined with WBRT can increase the intracranial response rate of patients with brain metastases of EGFR-mutated NSCLC,prolong PFS and OS,and its safety is controllable.It has a good clinical application prospect.